Thesis: Granules India's ₹192.5 crore ($~22M; CHF 20 million) acquisition of Swiss peptide CDMO Senn Chemicals AG, approved by its board on October 17, 2026, looks like a small deal — but it signals a much bigger structural shift. Peptide synthesis capacity, the obscure manufacturing layer behind GLP-1 weight-loss and diabetes drugs, is becoming a strategic asset. Indian generics makers are buying Swiss precision to position for the GLP-1 patent cliff. Biotech founders and investors should read the supply chain before they read the pipeline.
The news
Granules India received board approval to acquire 100% of Senn Chemicals AG, a Switzerland-based contract development and manufacturing organization (CDMO) specializing in peptide synthesis, for ₹192.5 crore (CHF 20 million). Senn specializes in both liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS), serving pharmaceutical, cosmetics, and theragnostics clients. The company reported revenue of CHF 26.9 million in 2023, with projections of CHF 19.6 million for 2024.
The deal is explicitly aimed at GLP-1 receptor agonists — the drug class behind the obesity and diabetes boom. The two companies were already co-developing two GLP-1-based APIs, and Granules' board also approved a new wholly owned Indian subsidiary (₹500 crore authorized capital, pending MCA approval) to support the acquisition.
What CDMOs do — and why peptide capacity is the bottleneck
A CDMO (contract development and manufacturing organization) develops and manufactures drugs on behalf of pharmaceutical companies, from clinical-trial material through commercial supply. The model exists because building specialized manufacturing is capital-intensive and technically demanding; outsourcing lets drug sponsors scale without owning plants.
Peptides sit at the hard end of this business. Unlike small-molecule drugs (made in chemical reactors with standard chemistry) or antibodies (made in bioreactors with living cells), peptides like semaglutide and tirzepatide are long chains of amino acids assembled one link at a time. The two methods:
- SPPS (solid-phase peptide synthesis): amino acids are built sequentially onto a solid resin support. It is flexible and fast to develop but expensive at scale, with solvent-heavy purification steps.
- LPPS (liquid-phase peptide synthesis): reactions run in solution, better suited to large-scale production with lower cost per kilogram once the process is locked.
Senn's mastery of both is the asset Granules is buying: SPPS for development and clinical supply, LPPS for commercial-scale manufacturing of GLP-1 APIs. As GLP-1 demand has exploded, peptide synthesis capacity — and the skilled chemists to run it — has become the binding constraint. You cannot sell a GLP-1 drug you cannot manufacture at scale, and capacity expansions take years to qualify with regulators.
Why an Indian generics maker is buying Swiss capacity
The logic is geographic arbitrage plus a patent-clock play: Senn brings specialized R&D expertise and established customer relationships in regulated markets; Granules brings cost-efficient, large-scale manufacturing.
- The GLP-1 patent cliff is coming. The first GLP-1 blockbusters will eventually lose exclusivity, and the generics and biosimilars race will be won by whoever has qualified, scaled peptide capacity first. Granules is buying its position years ahead of the cliff.
- Strategic independence. Relying on third-party CDMOs for your core growth franchise is a vulnerability; owning the capacity turns a supplier relationship into a moat — and a service business, since the CDMO can also sell capacity to other sponsors.
Note the price: CHF 20 million for a company doing ~CHF 20–27 million in revenue. That is roughly a 1x revenue multiple — a disciplined, even opportunistic price for specialized capacity, made possible partly by Senn's revenue softness (CHF 19.6 million projected for 2024, down from CHF 26.9 million in 2023).
The counterargument: small deal, crowded field
Skeptics will note that ₹192.5 crore is a rounding error next to the billions pouring into GLP-1 manufacturing globally. Dozens of CDMOs are expanding peptide capacity, and the large innovators are building their own. Senn's declining revenue raises questions about customer concentration and competitive positioning. Granules itself just reported a 6.41% drop in consolidated net profit to ₹117.60 crore for Q3 FY25 — the core business is under pressure even as it bets on peptides.
But land grabs are judged by the land: qualified peptide capacity with regulatory pedigree is genuinely hard to replicate quickly.
The signal for biotech founders and investors
For founders in obesity/diabetes: your manufacturing strategy is your commercial strategy. If you are developing a peptide therapeutic, secure CDMO capacity (or a capacity-owning partner) before you need it — the queue is the risk. Founders building novel peptide platforms (oral peptides, longer-acting formulations) should treat manufacturing partnerships as a fundraise milestone, not an afterthought.
For investors: the GLP-1 value chain is stratifying into molecule owners, API manufacturers, and fill-finish capacity. The middle layer — peptide CDMOs — is consolidating now, which means the window to invest in independent capacity is narrowing. Also watch the geography: India's generics giants are moving up the complexity ladder from small molecules to peptides, and the next step is oligonucleotides and complex biologics. The capability arbitrage trade has years to run.
For everyone: when a generics company pays 1x revenue for Swiss peptide expertise and immediately capitalizes a ₹500 crore Indian subsidiary around it, the industry is telling you where it thinks the next decade of volume lives. Follow the capacity.
Angeled.com connects founders building in biotech and life sciences with investors who understand the manufacturing behind the molecules.
Read Next
What a Reported $15B Raise at a $1.25T Valuation Would Mean for OpenAI — and Everyone Else
AlphaGenome 2 and the New Tooling Layer for Biotech Founders
Big Law Is Now Paying Lawyers to Learn AI — and That Changes Legal Tech
Biotech's $348 Million Week: Brain Drugs, Radiopharma and Gene Therapy
Databricks' Always-On Genie and the End of the Chatbot Era
Gemini Decision 1: Google's AI That Answers Instead of Chatting



